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Chancellor’s Honors Program Capstone Project  
Antibiotic Resistance Crisis 
 
Antibiotics have a clinical history almost a century long. Over that century, the burden of 
communicable diseases on the world population has diminished largely due to the widespread 
use of antibiotics. Though antibiotics greatly reduced deaths due to infectious disease, they also 
created new challenges in the form of antimicrobial resistance (AMR). Multiple drug resistant 
(MDR) pathogens are increasingly common and are considered grave threats to global health.  
 
Penicillin was the first antibiotic to be effectively used on a large scale. Alexander Fleming 
discovered penicillin by accident while studying Staphylococcus. One of his petri dishes became 
contaminated with a mold, and he noticed the bacterial growth was inhibited around the mold 
colony. He investigated this observation further and identified penicillin as the antibiotic agent 
produced by the mold. Fleming reported his finding in 1929, and briefly mentioned the 
possibility of using penicillin to treat localized infections (1). Fleming’s colleagues Ernst Chain 
and Howard Florey worked in collaboration with him over the next decade to develop methods 
for purifying penicillin and harvesting it in of sufficient amounts for human clinical trials (2). 
During the second world war, the United States and Britain jointly supported what became 
known as “The Penicillin Project.” Prior to the United States’ entry into the war, there was only 
enough penicillin available to treat less than 100 patients. By September 1943, there was enough 
penicillin for the demands of the United States armed forces and its allies (3). Penicillin 
undoubtedly saved many soldier’s lives during World War II and sparked the age of antibiotics. 
Subsequently, Fleming and his colleagues were awarded a Nobel Prize in 1945 for their 
discovery.  
 
The period following the discovery and success of penicillin is considered the golden age of 
antibiotics (Figure 1). The majority of antibiotics discovered during this time were isolated from 
natural sources. The primary sources of these antibiotics were actinomycetes, fungi, and other 
bacteria. Antibiotic producing bacteria are identified through a process called antibiotic 
screening. In the 1940’s Selman Waksman screened soil bacteria for antimicrobial properties 
through several culture-based techniques. These methods are based on the same principle: 
inhibition of a test strain over a closely cultivated indicator strain. The test strain is the strain 
suspected to produce an antibiotic compound targeting the indicator strain. The cross-streak 
technique is performed by creating horizontal streaks of the test and indicator strain that cross 
each other in the center of the plate. If the test strain produces an antimicrobial compound 
against the indicator strain, the growth of the indicator strain will be inhibited at the point that the 
horizontal streaks cross. Techniques such as cross-streaking have been used to create catalogues 
of antibiotic-producing microbes (Figure 2) (4). 
 
During the golden age between the 1940s and 1970s, twenty new classes of antibiotics were 
discovered(4). This coincided with a significant decrease in deaths due to infectious diseases. 
During the twentieth century, the leading cause of death in the United States gradually changed 
from communicable diseases like tuberculosis and pneumonia to non-communicable diseases 
like cardiac ischemia and cancer. At the beginning of the twentieth century, 46.4% of deaths 
were due to infectious disease. By the end of the century, the leading infectious diseases 
accounted for only 4.5% of deaths (5).  
 
 
However, the battle against infectious diseases is not over. Bacteria can develop resistance 
mechanisms that prevent antibiotics from interfering with cellular processes. These mechanisms 
include modification of the antibiotic target, efflux pumps, and the secretion of enzymes that 
degrade antibiotics. Modification of the antibiotic target occurs when there is a change in 
structure of that target. This change in structure is often due to mutations within the bacterial 
genome. The structural change of the target prevents the antibiotic from binding and the drug is 
no longer effective. Bacteria also employ efflux pumps that move toxins such as antibiotics from 
inside the cell to outside the cell. This prevents the antibiotic from reaching a critical 
concentration within the cell. Another mechanism of resistance is the secretion of enzymes 
targeting the antibiotic. These enzymes break down the antibiotic, so they are not effective (5).  
 
Antibiotic resistance was observed in pathogens shortly after the advent of antibiotics, and its 
dangers were anticipated by Alexander Fleming. During his Nobel prize acceptance speech in 
1945, he foreshadowed the dangers of antibiotic resistance (5): 
 
“But I would like to sound one note of warning… The time may come when penicillin 
can be bought by anyone in the shops. Then there is the danger that the ignorant man may 
easily under dose himself and by exposing his microbes to non-lethal quantities of the 
drug make them resistant.” 
 
Antibiotic resistance was first reported soon after the discovery of penicillin. A penicillin 
resistant strain of E. coli was identified in 1940 and many penicillin resistant strains of S. aureus 
were identified three years later (6, 7). Antibiotic resistance spread quickly in S. aureus, and by 
1960, 80% of all S. aureus infections were penicillin resistant (8). During the antibiotic golden 
age, scientist and pharmaceutical companies stayed ahead of resistance by continually 
discovering and producing new classes of antibiotics such as aminoglycosides, tetracyclines, and 
quinolones. These new classes of drugs targeted a variety of cellular processes including cell 
wall synthesis, protein synthesis, and DNA replication. This arms race against infectious disease 
resulted in the use of more potent broad-spectrum antibiotics and unfortunately produced 
multiple drug resistant (MDR) pathogens. MDR’s are considered to be one of the largest threats 
to global health. Extensively drug resistant tuberculosis was first identified in 2005, but has now 
been reported in 92 countries (5). The Centers for Disease Control (CDC) released a list of what 
is considered to be the biggest global health threats in 2015 and listed 18 drug-resistant 
pathogens as urgent, serious, or concerning threats. The report also states that about 2.8 million 
people in the US are infected with antibiotic resistant pathogens resulting in an estimated 35,000 
deaths annually. The World Health Organization (WHO) also considers MDR an urgent threat. 
In a 2015 report on antibiotic resistance, WHO listed MDR E. coli and tuberculosis among the 
top threats. According to WHO, 3.6% of all new and 20.2% of previously treated TB cases 
exhibit MDR.  
 
 
In Europe, a direct correlation was found between the amount of antibiotics prescribed and the 
levels of reported antibiotic resistance. Countries like France prescribe antibiotics more liberally 
and also report more cases of antibiotic resistance. Countries like the Netherlands prescribe far 
fewer antibiotics and also report lower levels of antibiotic resistance (9). This trend is likely due 
to unnecessary antibiotic use. Antibiotics are often prescribed to patients with viral illnesses or 
based on patient requests. In these situations, there is little evidence to support administering 
antibiotics to a patient. A 2016 study of prescribing practices in the United States determined that 
30% of oral antibiotic prescriptions were inappropriate. In cases of acute respiratory infections, 
the researchers deemed more than 50% of antibiotic prescriptions were unnecessary (10). 
Furthermore, a study in Finland found that a countrywide reduction of outpatient antibiotic 
prescriptions correlated to a significant decrease in the prevalence of erythromycin resistant 
Staphylococci (11).  
 
In addition to treating humans with bacterial infections, antibiotics are also used extensively in 
agriculture and livestock farming. Antibiotics serve several purposes in agriculture. They act as 
growth promoters by decreasing the microbial burden on the animal. A decreased microbial 
burden makes animals more efficient at absorbing nutrients from their food, which also makes 
them grow much faster (12). Antibiotics are also used to prevent the spread of disease among 
animal populations. High density farming practices encourage the rapid spread of microbial 
diseases, and these diseases pose a significant threat to the world’s food supply. In 2012, 2 
billion dollars in losses were attributed to S. aureus infections in dairy animals alone (13). To 
reduce the spread of disease, low doses of antibiotics are mixed with livestock food supplies. 
Animal consumption now accounts for about 80% of the total antibiotic use in the United States. 
This measure has helped ensure stable food supplies and that animal meat is safe for human 
consumption. However, it has also created a reservoir for the spread of antibiotic resistance. It is 
now believed that many multidrug resistance pathogens originated in animal food supplies (12, 
13).  
 
Multi-drug resistant pathogens are an increasing concern because there are few antibiotics able to 
kill these pathogens, and soon there may be none. During the age of rapid antibiotic 
development, new drugs were flooding into the market that could kill pathogens resistant to older 
drugs. Nowadays, however, the pharmaceutical industry has all but ceased antibiotic research 
and development, leaving little hope for a new wave of drugs to treat current MDR pathogens (5, 
14). Several factors contribute to the diminished incentive for pharmaceutical companies to 
continue antibiotic discovery. These issues include the fact that the costs associated with  drug 
development are enormous. A 2016 study estimateed the cost to bring a new drug to market in 
the United States was between about 1.3-2.5 billion dollars(15). The high costs associated eith 
drug development has led many pharmaceutical companies to switch to developing drugs for 
chronic diseases with large patient populations, which promise a large return on investment. For 
example, Humira is a monoclonal antibody drug used to treat chronic inflammatory disorders 
such as rheumatoid arthritis and Crohn’s disease. These chronic diseases represent large patient 
populations and have made Humira the highest selling drug by a wide margin for many years. 
Antibiotics, unlike Humira, are short term treatments and the potential patient population for new 
antibiotics is currently small(14).   There are several proposed avenues for slowing the spread 
and reducing the risk of antibiotic resistance. These approaches include renewing antibiotic 
research and development in order to provide new treatment options for current multidrug 
resistant pathogens. Additionally, reevaluating current prescription practices and reducing or 
eliminating the broad use of antibiotics in agriculture could also help to slow slow the spread of 
drug resistant pathogens.  
 
The antibiotic resistance crisis poses a significant threat to global health and the global economy. 
One study estimated the economic cost of a “worst-case scenario” for the AMR crisis. In this 
scenario, all bacteria eventually become MDR and antibiotics are no longer effective. The 
authors of this study found that in the US alone, healthcare cost tied to AMR would increase by 
20 billion dollars annually. They also estimated that a loss of productivity would account for 
another 35 billion dollars. If the AMR crisis continues to worsen, it could cost the US 55 billion 
annually, which the authors stated was “an underestimate”(16).  This results of this study 
emphasize the importance of solving the AMR crisis.  Alternative treatments for microbial 
diseases may be required to address this crisis.  Phage therapy, the use of viruses to treat 
bacterial infections, is one possible alternative. Phage therapy is being researched and tested with 





Viruses are obligate intracellular parasites and cannot replicate independently of a host organism 
Viruses lack DNA and RNA polymerases and ribosomes which are necessary for replicating the 
viral genome and creating proteins. For this reason, viruses must infect a host cell and use its 
machinery to create to replicate. Bacteriophages, or simply phages, specifically infect bacteria. 
Phages replicate within a host bacteria cell through either the lytic or the lysogenic life cycle. In 
the lytic replication pathway, the phage attaches to receptors on the cell surface and gain entry to 
the cell. The phage will then release its genome and replicate using bacterial machinery for 
transcription, translation, and genome replication. Once new phages have been assembled, they 
escape the host via lysis. Phages can lyse a cell many ways (i.e., inhibiting production of 
peptidoglycan or through the use of lytic enzymes)(17). The cycle continues as the viral progeny 
are released to infect new bacterial hosts. Lysogenic phages also begin the replication cycle by 
attaching and then inserting its genome. However, once inserted, the viral genome integrates in 
the host genome. At a later time, the viral genome will remove from the host genome and enter 
the lytic cycle. The activation of the lytic cycle is caused by physiological or environmental 





Viruses are highly diverse and can infect and kill all species of bacteria. Every species of 
bacteria is likely susceptible to one if not many species of phage. Phages’ ability to kill bacteria 
suggest they may have clinical potential. The use of phage as a treatment for bacterial infection 
is known as phage therapy. Phage therapy has been employed by many countries in the past with 
some success but has been largely ignored by most of the Western world until recently.  
 
Both lytic and lysogenic phages can be used for phage therapy. Lytic phages are preferred for 
phage therapy because they lyse bacteria more quickly and reliably. Lysogenic phages would be 
less effective because their lytic action would be difficult to predict. There are concerns that both 
lytic and lysogenic phages could have negative side effects. A highly lytic phage may lead to the 
release of bacterial endotoxins that could worsen the condition of a patient. Lysogenic bacteria 
also pose a risk. They could carry virulence or antibacterial genes that may be conferred to 
bacteria when the viral genome integrates with the host(19). 
 
There is immense potential in phage therapy due to the way phages infect and kill bacteria. First, 
they are highly abundant and highly specific (17, 20). Each phage strain usually infects one type 
of bacteria, although some phages can infect several strains (21). Phage specificity could have 
reduced side-effects compared to antibiotics. Antibiotics affect broad ranges of bacteria, which 
increases side effects for patients. For example, broad acting antibiotics can reduce bacterial 
diversity in the gut microbiome and contribute to diseases such as Crohn’s disease (22). 
Furthermore, these antibiotics increase the development of antibiotic resistance by targeting 
many species of bacteria. Because phages only target bacteria within a narrow host range, phage 
therapy would contribute less to the development of resistance than antibiotics. Phages acts on 
fewer species of bacteria; therefore, fewer bacterial species have the ability to develop resistance. 
Horizontal gene transfer also contributes to the spread of resistance among bacteria. Antibiotics 
act on many species of bacteria so many species are incentivized to acquire antibiotic resistance 
genes through horizontal gene transfer. Phage therapy produces less selective pressure for 
bacteria to acquire these genes through horizontal gene transfer. For example, S. aureus would 
not be incentivized to acquire resistance for a phage that only infects E. coli, thus reducing the 
spread of resistance among different species of bacteria and shrinking the potential reservoir for 
AMR. The kinetic properties of phage therapy are also an appealing quality. Phages are self-
amplifying. A few phages may infect a cell, but after replication hundreds to thousands of new 
phages will be released. Due to phage’s self-amplifying nature, the amount of phage can grow 
over time rather than decrease over time as with antibiotics. Hypothetically, smaller and less 
frequent doses of phage would be sufficient to clear an infection (17). These qualities make 
phage therapy an appealing alterative to antibiotics in the midst of the antibiotic resistant crisis.  
 
History of Phage Therapy: 
 
Phages were discovered by English bacteriologist Frederick Twort in 1915 (23). French-
Canadian Félix D’Herelle was the first to describe plaque assays in 1917 (24). During 
D'Herrelle’s investigation, he conducted plaque assays on stool samples from dysentery patients. 
He noted the phage titer was low at the beginning of the illness and highest following recovery. 
He concluded that the development of phage specific for pathogenic bacteria was responsible for 
patient recovery. This conclusion, though not entirely accurate, sparked a period of enthusiastic 
research into phage and their clinical potential (25, 26). D’Herelle continued investigating phage 
and conducted clinical studies in both humans and animals. He was known to determine the 
safety of his phage treatments by first administering phage to himself and then family members 
and coworkers. During the 1920’s, D’Herelle conducted several studies and reported positive 
results. In one such study, D’Herelle treated four patients with the bubonic plague by injecting 
phage into their buboes. The patients then displayed an impressive recovery from the plague. 
They conducted another study on cholera patients. The treatment group of 12 patients was given 
oral phage and only one patient died. The control group was given no phage and 12 of the 18 
patients died (26, 27). In its early days, phage therapy was displaying success. Unfortunately, the 
enthusiastic beginnings of phage therapy did not last.  
 
This period was believed by many at the time to be overly optimistic. Some scientists began to 
point out flaws in phage clinical studies and the general lack of knowledge regarding phage 
biology. In 1934, American doctors Stanhope Baynes-Jones and Monroe Eaton released a highly 
critical review of phage therapy clinical studies. Eaton and Baynes pointed out the absence of 
controls in the studies being conducted. At the time, there was no consistency in the way phage 
was being prepared, dosed, or administered. There was also no established method for analyzing 
results. Many of the human studies were conducted on self-limiting and non-fatal diseases 
making it impossible to distinguish with certainty the role phage played in those patients’ 
recovery. Eaton and Baynes suggested that phages must first be proven effective in vitro and 
then in animal models before human studies occur. In the end, Eaton and Baynes believed the 
phage therapy movement was disorganized and lacked the ability to explain or prove the actions 
of phage in vivo (28).   
 
The Eaton-Baynes report tempered much of the enthusiasm surrounding phage therapy in the 
United States. Following its publication, the general view of phage therapy became more 
negative. The West mostly turned its attention to antibiotics, which were effective and mass 
produced easily following World War II. Countries in the East like Georgia and the Soviet Union 
continued to use phage therapy. In Georgia, phage cocktails were developed to treat various 
ailments. These cocktails contained many different phages that could target a variety of 
pathogenic bacteria. Some of these cocktails were available to the public without prescription. 
One such cocktail, “Pyophage,” was applied to wounds and also came in the form of a bandage 
that would slowly release phage over time. In the Soviet Union, phage therapy was focused on 
treating ailments of war like diarrheal and gangrene infections. Though the Eastern world had 
long, successful experiences with phage therapy, much of their practices were kept secret prior to 
the collapse of the Soviet Union. It wasn’t until the 1990’s, when scientists were gaining access 
to the Russian and Eastern European literature that interest in phage therapy began to gain 
momentum. At the time, the growing threat of antibiotic resistance was also driving the search 
for alternative treatments (25).  
 
While Eastern countries were embracing phage therapy, the Western world had all but ceased 
clinical studies in the field. Some scientist continued to examine phage therapy in animal models, 
and only a handful of human studies occurred. During the 1960’s the World Health Organization 
sponsored a clinical trial in Pakistan. In the study, acutely ill cholera patients were given high 
doses of anti-cholera phage. The patients given phage treatments did not recover any faster than 
patients given the typical antibiotic treatment. A subsequent study was conducted with a larger 
patient population and more controls. The results were similar to the primary study (29). The 









Current Studies in Phage Therapy: 
  
Research in the field of phage therapy is now actually booming as the search for antibiotic 
alternatives continues. Many safety studies have been conducted in recent years to evaluate the 
tolerability of phage therapy. These studies have evaluated various phages and subjects with 
various ailments. A study in Australia examined the safety of a phage treatment in 13 subjects 
suffering from serious Staphylococcus aureus infections. They were treated with myoviridae 
phage intravenously twice daily for 14 days. The subjects were monitored for fever, tachycardia, 
hypotension, hepatic dysfunction, and other systemic effects. The subjects exhibited no adverse 
effects. The study concluded that myoviridae phage administered intravenously for patients with 
Staphylococcus aureus infections, endocarditis, and septic shock is safe. The study, however, 
made no assessment of the phage treatment’s efficacy (30). Another safety study evaluated the 
tolerability of phage cocktails in subjects with recurring sinus infections caused by 
Staphylococcus aureus that were unsuccessfully treated by other means. This Phase I trial 
examined 9 subjects in 3 cohorts receiving ascending phage doses. The phage was administered 
by intranasal irrigation twice daily for 14 days. The patients exhibited no fever and no significant 
changes in vital signs. Only minor side effects associated with the intranasal irrigation were 
reported. The study concluded that phage administered by intranasal irrigation was safe and 
showed preliminary signs of efficacy (Figure 4). 2 of the 9 patients showed evidence of 
Staphylococcus Aureus eradication. (31).  
 
Scientist are also searching for new phages that may be effective therapeutics. These studies 
have been conducted both in vitro and in animal models. An exploratory study out of India 
published in 2019 characterized the efficacy of various phages against E. coli. Samples of blood, 
stool, urine, and sputum were collected from various medical facilities, and phages with lytic 
activity against E. coli were isolated. Over 50 phages were isolated and characterized by host 
range and other metrics such as adsorption rate. One of the phages, myPSH1131, was then 
selected to conduct further in-vivo testing with G. mallonella larvae, which are often used to 
model bacterial infections. myPSH1131 was found to be effective against five strains of E. coli 
both in vitro and in vivo. The study suggests that myPSH1131 could potentially go on to safety 
and clinical trials (21). Another study published in 2019 tested phages against antibiotic resistant 
strains of E. coli, K. pneumonia, and E. aerogenes. Phages were isolated from the Ganges river 
in India. Three of the isolated phages were identified for further testing. These were E. coli virus 
myPSH 2311, Enterobacter virus myPHS1140, and Klebsiella virus myPSH 1235. The phages 
were tested in vitro to determine latency period, adsorption rate, and burst size. The three phages 
were combined as a phage cocktail and tested in vitro against the antibiotic resistant bacteria. 
Bacterial growth declined after 2 hours until after 24 hours there were no viable cells. The 
cocktail was effective in vitro against the resistant strains of bacteria (21). These exploratory 
studies will help establish phage banks for future development of phage therapies.  
  
One specific area of interest in current phage therapy research is modulation of the gut 
microbiome. The gut microbiome is a crucial part of the overall health of the host. It helps 
protect against pathogenic infections, modulates the immune system, and influences homeostasis 
of the gut itself (32, 33). Dysbiosis of the gut microbiome has also been implicated in several 
diseases including obesity and Crohn’s disease (34, 35). Phages naturally play an important role 
in modulating the gut microbiome. Patients with Crohn’s disease were found to have lower 
phage diversity in their microbiomes than healthy persons (36). This suggests that phages could 
be used to treat diseases associated with gut microbiome dysbiosis.  
 
There have been several clinical studies investigating the efficacy of phage therapy as a gut 
microbiome modulator. A safety study conducted in 2018 aimed to determine the tolerability of a 
phage cocktail targeting E. coli in 32 healthy adults with mild to moderate gastrointestinal 
distress. The subjects in this randomized, double-blinded, placebo-controlled study consumed a 
capsule containing a cocktail of four phages daily for 28 days. The subjects underwent  
comprehensive metabolic panels and answered health questionnaires over the course of the 
study. The mean values of the patient’s metabolic levels remained within acceptable values and 
no adverse health effects were observed. The study concluded that the phage cocktail was safe 
and tolerable for the human population (37).  
 
Results from a clinical trial using the same phage cocktail was published in 2019 and examined 
how phage treatment affected the overall gut microbiome. The study was conducted on 36 
subjects with self-reported gastrointestinal issues. It was found that the phage treatment had little 
effect on the overall composition of the microbiome but that it actually reduced inflammation. 
This study was randomized, double-blinded, and placebo controlled. The subjects took daily 
capsules of the phage cocktail over the course of two 28-day treatment periods. Stool samples 
were collected and DNA was extracted to measure changes in the gut microbiome composition. 
Plasma was also drawn to measure levels of inflammatory signaling. ELISA tests were run on 13 
cytokines and chemokines. The study found that the treatment subjects exhibited a 71% decrease 
in E. coli population compared to pretreatment levels (Figure 5). The control subjects exhibited a 
47% reduction of E. coli.  The overall microbiome composition was largely unchanged due to 
the phage treatment. Only a few species of bacteria showed population changes correlated with 
reduction of E. coli in the microbiome. This is advantageous because antibiotic treatment often 
leads to significant decreases in the gut microbiome diversity and produces dysbiosis (22). The 
treatment group also showed a mean 10% decrease in IL-4 signaling from t=0 to t=28 while the 
placebo group showed a 2% decrease (Table 1). The authors suggest this decreased inflammatory 
signaling could be due to lower levels of circulating LPS resulting from the phage killing of E. 
coli (38). These studies have produced largely positive results. None of the studies report and 
significant adverse effects. These results bode well for the future of phage therapy.    
 
Challenges to Phage Therapy: 
 
While phage therapy has shown some success in recent studies, there are several considerations 
that must be addressed before it can advance as a treatment. One challenge is standardization of 
methods. In the past, dosing practices have been inconsistent across the field. The inconsistency 
is in part because phages present challenges to the conventional dosing practices used for 
antibiotics. Antibiotic dosing strategies are more simplified due to single-hit bacterial killing 
kinetics. Phage therapy dosing is more complex due to the nature of phages. As stated 
previously, phages are self-amplifying which is not the case with pharmaceutical drugs. Different 
phages kill bacteria at different speeds. Critical densities of phage must be achieved at the 
infections site. Phage efficacy is also influenced by the density of the bacterial population. Due 
to these factors, determining phage therapy dosing is a difficult task (20, 39, 40). 
 
Another complicating factor are interactions between the immune system and the phage. These 
interactions must be well understood when evaluating phage therapy efficacy and safety. Drugs 
can often enhance the immune response in a positive way, but they can also have adverse effects. 
Phages have been shown to enhance the innate immune response by controlling bacterial density 
and displaying adjuvant activity. Phage therapy has been associated with increased cytokine 
signaling leading to a more effective immune response. Phage therapy has also been shown to be 
dependent on the immune system to fully clear a bacterial infection (41). A 2017 study using 
mouse models verified the importance of phage-immune system interactions. Mice with 
pneumonia caused by P. aeruginosa were treated with phage. Mice with fully functioning 
immune systems were able to clear the infections while neutrophil and lymphocyte deficient 
mice were unable to clear the infection. This suggests that phage therapy is dependent on the 
immune system to completely eliminate a bacterial infection (42). In other cases, the immune 
system interactions present differently. Other studies have shown little influence on cytokine 
signaling (43). These varying degrees of immune system interactions suggest that the 
relationship between phages and the immune system may be case specific. These interactions 
must be well understood before the therapies can be considered safe, predictable, and effective.  
 
Another challenge to the success of phage therapy are bacteria’s ability to acquire phage 
resistance. Bacteria have many antiviral mechanisms like clustered regularly insterspaced short 
palindromic repeats( CRISPR). CRISPR is a gene editing system in bacteria that creates a 
memory of past viral infections by incorporating portions of the viral genome into the bacteria 
genome. Bacteria also utilize constantly evolving surface receptors that prevent viral attachment 
and restriction-modification systems that can destroy foreign DNA. Phage can also evolve to 
overcome these antiviral mechanisms (44). The coevolution between bacteria and phage is an 
important consideration for phage therapy efficacy. Studies have found that the speed of 
resistance is highly variable. In one human trial, bacteria developed phage resistance in 
anywhere from 17% (S. aureus) to 85% (E. coli) of treatments (45). Often the phage will have 
reduced the bacterial population enough that the immune system can clean up any phage resistant 
bacteria. The concern is the potential selection for bacteria containing these antiviral genes. 
Subsequent horizontal gene transfer could potentially spread these genes within the bacterial 
population (45). The spread of phage resistance could be reduced by the use of phage cocktails. 
These cocktails are made up of several phages that in combination are broad acting and target 
several bacterial mechanisms. Phage cocktails reduce the chance that resistant bacteria survive 
(46). Reducing the threat of phage resistant bacteria will be an important consideration for the 




Phage therapy has had a long and winding history. The past decade has seen phage therapy 
return to scientific prominence as the search for antibiotic alternatives continues. The field has 
gained significant momentum and the human trials have shown largely positive results. These 
encouraging results will spur continued research and development. Phage therapy could 
potentially minimize the threat of multi-drug resistant pathogens, and it may not be long before 
phage therapy is a common treatment for a variety of bacterial infections and diseases.  
  








Figure 2: Culture based techniques for screening antibiotic producing microbes 
 
  




Figure 4: For the Lund-Kennedy Score (LKS), scores range from 0-20, with higher scores 
indicating worse endoscopic disease; Sino-Nasal Outcome Test-22 (SNOT-22), scores range from 
0-110, with higher scores indicating worse symptoms; and visual analog scale (VAS), scores 








Figure 5: Change in E. coli levels from baseline values after treatment or placebo consumption. 
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